Currently set to No Index
Currently set to No Follow
Logo NVDO

Best meeting abstracts, Indifferent

  • F.W.J. Boot (Leiden) schreef:

    Congratulations on your best abstract!!

  • Arnaud Zaldumbide schreef:

    Congratulations!!!!!

  • bertjanpottervanloon schreef:

    Beautiful presentation, I hope and expect you will get it in a high ranking journal !
    In islet transplantation islets containing alpha and beta cells ( and probably gamma cells) are reinfused; here you focussed on beta cells; does infusing beta cells only result in different profiles of insulin release compared to islets ? and is it a benefit not having glucagon secreting cells ? ( less cance of DKA, but also less adaptation to hypoglycaemia). Thes questions are not directly included in your presentation, yet for a clinician relevant.
    Thanks again

    • B. Rajaei (Leiden) schreef:

      Thanks for the comment. There is a kind of controversy discussion on this subject. Some scientists believe It is likely that islet non–Beta cells are not essential for successful islet transplantation and they propose to purify the beta cells. Wheras some others think that the relationship between Beta cells and alpha cells is needed for successful transplantation. At the moment, we don’t have plan to purify the cells. By the current differentiation protocol both beta cells and alpha cells are produced and since the stage 7 of this protocol is in favour of beta cells, the number of produced beta cells is higher than alpha cells.

  • t.nikolic@lumc.nl schreef:

    Congratulations! Very interesting work. I may have missed it, but did you test HLA expression on your beta-like cells? For the clinical application, it may be interesting to know whether and how these cells will be seen by the immune system.

    • B. Rajaei (Leiden) schreef:

      Thanks for the comment. We haven’t checked the HLA yet but it is an important point that should be taken into account when we move towards the clinics. On the other hand, recently, scientists have proposed the CRISPR-Cas9 gene-editing system to create the pluripotent stem cells that are functionally “invisible” to the immune system and prevented rejection of stem cell transplants. Because these “universal” stem cells can be manufactured more efficiently than patient specific stem cell- derived Beta cells made for each patient.There are also some immunoprotective devices available that protect the cells after transplantation.

  • >